Targeting CXCR1/2 in the first multicenter, double-blinded, randomized trial in autologous islet transplant recipients.
Targeting CXCR1/2 in the first multicenter, double-blinded, randomized trial in autologous islet transplant recipients. Am J Transplant. 2021 11; 21(11):3714-3724.